Biotech Values

[DewDiligence]

KNSA/REGN—FDA approves Arcalyst (rilonacept) for recurrent periocarditis:

https://finance.yahoo.com/news/kiniksa-announces-fda-approval-arcalyst-203000531.html

Kiniksa licensed ARCALYST from Regeneron in 2017 for evaluation in diseases believed to be mediated by both IL-1alpha and IL-1ß, including recurrent pericarditis. Upon this approval by the FDA for recurrent pericarditis, Kiniksa takes responsibility for sales and distribution of ARCALYST for all the approved indications in the United States, including CAPS and DIRA, and will evenly split profits with Regeneron, as described in the ARCALYST License Agreement.

KNSA is +19% in AH trading. CC at 5:30pm ET.